Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation
Takanori Ikeda(Toho University), Hiroaki Shimokawa(Tohoku University), Masahiro Kamouchi(Kyushu University), Shinichiro Uchiyama(International University of Health and Welfare), Yasuo Okumura(Noguchi Hospital), Ichiro Sakuma(Hokko Memorial Hospital), Naoki Matsumoto(St. Marianna University School of Medicine), Takeshi Yamashita(Cardiovascular Institute Hospital), Hideo Morimoto(Fukuyama City Hospital), Junya Ako(E Ink (South Korea)), Takanari Kitazono(Kyushu University), Hirotsugu Atarashi, Koji Fukuda(International University of Health and Welfare), Shogo Shimizu(Gifu Prefectural General Medical Center), Nobuyoshi Sugishita, Koichi Kaikita(Kumamoto University), Akihito Tsuchida(Sapporo Minami Hospital), Hiroshi Inoue(Toyama University Hospital), Keijiro Saku(Fukuoka University Hospital), Hideki Origasa(University of Toyama), Yuichiro Nakamura(The Nakamura Hajime Eastern Institute), Wataru Shimizu(Nippon Medical School Hospital)
Cited by 14
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
|European Heart Journal|2018|2.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823